Quarterly ResultJul 30, 2026, 04:38 PM
PTC Therapeutics Q2 Net Income $83.5M; Revenue $360.5M, up 101.5%
AI Summary
PTC Therapeutics reported a net income of $83.5 million for the second quarter of 2026, a significant improvement from a net loss of $64.8 million in the same period last year. Total revenues surged by 101.5% to $360.5 million, driven by strong net product revenue and a $50.0 million milestone payment from Novartis for the initiation of the votoplam Phase 3 clinical trial. The company also announced positive 24-month interim analysis results for votoplam in Huntington's disease and plans for new studies for vatiquinone and other pipeline candidates.
Key Highlights
- Q2 2026 net income was $83.5 million, compared to a net loss of $64.8 million in Q2 2025.
- Total revenues for Q2 2026 increased 101.5% to $360.5 million from $178.9 million in Q2 2025.
- Net product revenue grew 101.8% to $238.8 million in Q2 2026 from $118.3 million in Q2 2025.
- Collaboration and license revenue was $50.6 million in Q2 2026, including a $50.0 million Novartis milestone.
- Diluted earnings per share for Q2 2026 was $0.92, up from a loss of $0.83 per share in Q2 2025.
- Novartis initiated the global Phase 3 clinical trial for votoplam, triggering a $50.0 million milestone payment.
- Votoplam PIVOT-HD 24-month interim analysis showed 52% slowing of disease progression in Stage 2 HD patients.
- Company plans to initiate PROVE-FA open label study for vatiquinone in Q3 2026.
Price Impact
More from PTCT